Plasminogen Activator Inhibitor-1 Polymorphism Confers a Genetic Contribution to the Risk of Recurrent Spontaneous Abortion: An Updated Meta-Analysis

Zhan, Huang; Tang, Wen; Liang, Zhikun; Chen, Qiaopei; Li, Mingyi; Li, Yingfeng; Lao, Shaoxing; Huang, Li-Ying; Huang, Min; Hu, Xuehua; Zhao, Jianping

doi:10.1177/1933719117702013

Cited by 8 publications

(12 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another meta-analysis, was made by [9], they used new and more rigorous inclusion criteria: 1-evaluate the association between PAI-1 4G/5G with the risk of recurrent abortion, 2-studies case-control, our projected with cohort 3-Studies with enough information to infer results. This analysis showed that there is an association of PAI-1 4G/5G with recurrent abortion in Caucasians, Asians and Africans, but not in Latinos.…”

Section: Resultsmentioning

confidence: 99%

PAI-1 and Recurrent Abortion

Lara¹,

A²

2018

PRM

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

PAI-1 and Recurrent Abortion

Lara¹,

A²

2018

PRM

View full text Add to dashboard Cite

show abstract

“…96 Similarly, meta-analyses investigating the association between PAI-1 4G/5G polymorphism and recurrent pregnancy loss found a significant association between 4G/4G genotype and recurrent pregnancy loss. 97 98 99 However, Su et al reported no association between recurrent pregnancy loss and PAI-1 4G/4G genotype. 100 Thus, the conflicting results found in this paper are also reflected in contradictory results of previous published meta-analyses.…”

Section: Discussionmentioning

confidence: 99%

“…Recent meta-analyses have investigated the association between the PAI-1 4G/5G polymorphism and adverse pregnancy outcomes. 96 97 98 99 100 Zhao et al reported significantly higher risk of preeclampsia in women carrying the 4G/4G genotype. 96 Similarly, meta-analyses investigating the association between PAI-1 4G/5G polymorphism and recurrent pregnancy loss found a significant association between 4G/4G genotype and recurrent pregnancy loss.…”

Section: Discussionmentioning

confidence: 99%

The Role of Plasminogen Activator Inhibitor Type 1 (PAI-1) in Placenta-Mediated Pregnancy Complications: A Systematic Review

Agersnap

Nissen

Hvas

2022

Semin Thromb Hemost

View full text Add to dashboard Cite

Plasminogen activator inhibitor type 1 (PAI-1) is a main inhibitor of fibrinolysis. The PAI-1 gene (SERPINE1) harbors genetic variants with the potential of modifying plasma levels of PAI-1. A delicate balance exists between the coagulation and fibrinolytic system, and changes in PAI-1 have been suggested to compromise establishment of a successful pregnancy. Therefore, this systematic review investigated the association between genetic variants and/or plasma levels of PAI-1 and placenta-mediated pregnancy complications. An extensive literature search was conducted in PubMed, Embase, and Web of Science on the 29th of April 2021. All studies underwent quality rating according to The Study Quality Assessment Tools checklist provided by National Heart, Lung and Blood Institute. A total of 71 studies were included, among which 60 studies investigated PAI-1 genotypes and 11 studies measured PAI-1 plasma levels. In 32 out of 59 studies, no association was found between the PAI-1 4G/5G polymorphism (rs1799768) and placenta-mediated pregnancy complications, which was stated as no significant difference in the genotype distribution comparing women with and without placenta-mediated pregnancy complications or no significantly increased odds of placenta-mediated pregnancy complications carrying the 4G/4G or 4G/5G genotype. Eight out of 11 studies reported significantly higher PAI-1 plasma levels in preeclamptic women than in women without preeclampsia. In conclusion, no clear evidence indicates that PAI-1 polymorphisms are associated with placenta-mediated pregnancy complications, and the possible association between high PAI-1 plasma levels and preeclampsia needs further investigations. Thus, investigation of PAI-1 genotypes and PAI-1 plasma levels does not currently seem to have a place in daily clinical practice managing placenta-mediated pregnancy complications.

show abstract

“…The etiology of RPL is complicated, and several risk factors are involved in the development of the disease. In addition to fetal and maternal factors, including chromosomal abnormalities, endocrine and metabolic aberrations, and autoimmune abnormalities, genetic single nucleotide polymorphisms at different loci, also play essential roles in RPL ( 6 , 12 , 39 ) . In this meta-analysis, we evaluated the association of the ACE I/D and PAI-1 4G/5G polymorphisms with RPL risk in Iranian women from all eligible case-control studies.…”

Section: Discussionmentioning

confidence: 99%

“…Thrombotic disorders are detectable in 40-50% of RPL cases ( 11 ) . It has been presumed that the etiology of RPL is associated with factors involved in fibrinolysis and coagulation ( 3 , 12 ) . In the past two decades, several investigators suggested that thrombophilia had an impact on susceptibility to RPL ( 13 , 14 , 15 ) .…”

Section: Introductionmentioning

confidence: 99%

A meta-analysis of the association of the ACE I/D and PAI-1 4G/5G polymorphisms with recurrent pregnancy loss in Iranian women: Are the investigations adequate?

Dastgheib¹,

Karimi-Zarchi²,

Bahrami³

et al. 2021

tjod

View full text Add to dashboard Cite

The associations of ACE I/D and PAI-1 4G/5G polymorphisms with recurrent pregnancy loss (RPL) in Iranian women have yielded controversial results. Thus, we conducted a meta-analysis to obtain more certain results. A comprehensive literature search was performed in the PubMed, Web of Sciences, Scopus, MedRxiv, SID, and CNKI databases up to January 1st, 2021, using the appropriate terms. All case-control studies were included. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to estimate the strength of associations. A total of 14 studies including eight studies with 783 patients and 761 healthy subjects on ACE I/D and six studies with 1.155 patients and 699 healthy subjects on PAI-1 4G/5G were included. Combined data revealed that ACE I/D polymorphism was significantly associated with RPL risk in Iranian women under three models i.e., allele [OR=0.744, 95% CI: (0.640-0.864); p≤0.001], dominant [OR=0.774, 95% CI: (0.601-0.996); p=0.047], and recessive [OR=0.767, 95% CI: (0.611-0.963); p=0.022]. Moreover, the pooled data showed a significant association between the PAI-1 4G/5G polymorphism and RPL risk under all five models i.e., allele [OR=2.352, 95% CI: (1.623-3.408); p≤0.001], heterozygote [OR=8.364, 95% CI: (4.744-14.756); p≤0.001), homozygote [OR=2.192, 95% CI: (1.093-4.394); p=0.027), dominant [OR=2.354, 95% CI: (1.309-4.235); p=0.004], and recessive [OR=5.208, 95% CI: (3.005-9.025); p≤0.001]. Stratification analysis revealed that these polymorphisms were associated with RPL risk by the number of miscarriages. Our pooled data indicated that ACE I/D and PAI-1 4G/5G polymorphisms were significantly associated with an increased risk of RPL in Iranian women. These significant findings showed that the investigation might be adequate for ACE I/D and PAI-1 4G/5G polymorphisms in the Iranian population.

show abstract

Plasminogen Activator Inhibitor-1 Polymorphism Confers a Genetic Contribution to the Risk of Recurrent Spontaneous Abortion: An Updated Meta-Analysis

Cited by 8 publications

References 49 publications

PAI-1 and Recurrent Abortion

PAI-1 and Recurrent Abortion

The Role of Plasminogen Activator Inhibitor Type 1 (PAI-1) in Placenta-Mediated Pregnancy Complications: A Systematic Review

A meta-analysis of the association of the ACE I/D and PAI-1 4G/5G polymorphisms with recurrent pregnancy loss in Iranian women: Are the investigations adequate?

Contact Info

Product

Resources

About